Every 8-K that Mobia Medical, Inc. (MOBI) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow MOBI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MOBI filings page.
Mobia Medical, Inc.’s Board of Directors appointed Myriam J. Curet, M.D., to its nominating and corporate governance committee on October 15, 2026, effective immediately. The amendment supplements Mobia’s August 3, 2026 report solely to disclose the appointment; all other disclosures in that report remain unchanged.
Mobia Medical, Inc. amended its earlier current report solely to add a committee appointment. On October 15, 2026, its board appointed Reza Zadno, Ph.D., to serve on the audit committee, effective immediately. He will continue serving on the compensation committee. The amendment states that all other disclosures in the July 15, 2026 report remain unchanged.
Mobia Medical, Inc. reported second quarter 2026 results with revenue of $13.5 million, an increase of 102% from $6.7 million a year earlier, driven by higher adoption of the Vivistim System and more IPG units sold. Gross profit was $11.2 million, and gross margin was 83.2% compared with 82.3% in the prior-year quarter.
Operating expenses rose to $29.2 million, up 83% from $16.0 million, reflecting expanded commercial personnel, commissions, development, and administrative costs. Net loss was $21.0 million, or $1.10 per share, versus a net loss of $10.5 million, or $12.44 per share, mainly due to higher expenses and a change in fair value of convertible notes.
As of June 30, 2026, cash and cash equivalents totaled $177.1 million, including approximately $134.0 million in net proceeds from an initial public offering completed in May 2026. For full year 2026, the company expects revenue of $54.0 million to $56.0 million, representing growth of 69% to 75% over 2025.
Mobia Medical, Inc. expanded its Board of Directors from seven to eight members effective July 30, 2026 and appointed Myriam J. Curet, M.D. as a new Class II director. Her term runs until the company’s 2028 annual meeting of stockholders, or until a successor is elected and qualified.
The Board determined that Dr. Curet qualifies as an independent director under SEC and Nasdaq rules. She is not yet assigned to any Board committee and will receive compensation under Mobia’s non-employee director compensation program, along with the company’s standard indemnification agreement. The company states there are no related-party transactions with Dr. Curet requiring disclosure.
Mobia Medical, Inc. expanded its Board of Directors from six to seven members and appointed Reza Zadno, Ph.D. as a new Class III director. His term extends until Mobia’s 2029 annual meeting of stockholders, or until a successor is elected and qualified or he departs earlier.
Dr. Zadno was also appointed to the Board’s Compensation Committee, which now comprises Casey Tansey (chair), Dana Mead and Dr. Zadno, following Dr. William Harrington’s resignation from the committee. The Board determined that Dr. Zadno qualifies as an independent director under SEC and Nasdaq rules. He brings prior CEO experience at PROCEPT BioRobotics Corporation and Avedro, Inc., as well as multiple medical device and biopharma board roles. He will be compensated under Mobia’s non-employee director compensation program, and Mobia expects to enter into its standard indemnification agreement with him.